IDWeek 2022。华盛顿特区——2022年10月19日至23日

IF 0.2 4区医学 Q4 Medicine

Drugs of The Future Pub Date : 2023-01-01 DOI:10.1358/dof.2023.48.1.3521795

J. Nguyen

{"title":"IDWeek 2022。华盛顿特区——2022年10月19日至23日","authors":"J. Nguyen","doi":"10.1358/dof.2023.48.1.3521795","DOIUrl":null,"url":null,"abstract":"IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP). For the first time since the COVID-19 public health emergency began, IDWeek 2022 returned to in-person attendance. It was held in Washington, D.C., and the meeting comprised 5 days of live sessions and on-demand content that included posters and oral presentations.","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"IDWeek 2022. Washington, D.C. - October 19-23, 2022\",\"authors\":\"J. Nguyen\",\"doi\":\"10.1358/dof.2023.48.1.3521795\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP). For the first time since the COVID-19 public health emergency began, IDWeek 2022 returned to in-person attendance. It was held in Washington, D.C., and the meeting comprised 5 days of live sessions and on-demand content that included posters and oral presentations.\",\"PeriodicalId\":11366,\"journal\":{\"name\":\"Drugs of The Future\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs of The Future\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1358/dof.2023.48.1.3521795\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs of The Future","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1358/dof.2023.48.1.3521795","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

IDWeek是美国传染病学会(IDSA)、美国卫生保健流行病学学会(SHEA)、艾滋病医学协会(HIVMA)、儿科传染病学会(PIDS)和传染病药剂师学会(SIDP)的联合年会。自2019冠状病毒病突发公共卫生事件开始以来，IDWeek 2022首次恢复了现场出席。会议在华盛顿特区举行，会议包括5天的现场会议和点播内容，包括海报和口头报告。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

IDWeek 2022. Washington, D.C. - October 19-23, 2022

IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP). For the first time since the COVID-19 public health emergency began, IDWeek 2022 returned to in-person attendance. It was held in Washington, D.C., and the meeting comprised 5 days of live sessions and on-demand content that included posters and oral presentations.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drugs of The Future 医学-药学

CiteScore

0.30

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： A leading international, peer-reviewed biomedical research journal publishing articles on topics emerging from the confluence of fields including chemistry, biology, pharmacology, genomics and medicine, and addressed to scientists and researchers involved in drug design, discovery and development, target identification and validation, and the preclinical and clinical development of treatments for common as well as rare and neglected diseases and conditions. The journal publishes monographs containing comprehensive product information on new compounds in development, including synthesis, preclinical pharmacology, pharmacokinetics and metabolism, safety, clinical studies and drug interactions, as well as review articles on a variety of topics, congress and meeting reports.